Amphora Medical offers a polymer‑based transdermal patch platform that delivers small‑molecule and biologic APIs with zero‑order release over 24–72 hours. The system replaces oral or injectable dosing with a non‑invasive, adhesive patch, improving medication adherence and enabling pharmaceutical partners to commercialize scalable, patient‑centric chronic‑therapy formulations.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic diseases often struggle to maintain consistent dosing schedules when using oral tablets or injectable therapies, leading to suboptimal therapeutic outcomes and increased healthcare costs. Invasive administration routes can also cause discomfort and reduce willingness to adhere to long‑term treatment plans.
Solution
Amphora Medical provides a proprietary transdermal patch platform that delivers active pharmaceutical ingredients through the skin at a controlled, sustained rate. The system replaces oral or injectable dosing with a non‑invasive, adhesive patch that can be applied by the patient and left in place for the prescribed duration. By maintaining steady plasma concentrations, the patches improve medication adherence and reduce the variability associated with traditional delivery methods. The technology is compatible with a broad range of small‑molecule and biologic APIs, enabling pharmaceutical partners to develop convenient, patient‑centric formulations for chronic indications. Manufacturing processes are designed for scalability and regulatory compliance, facilitating rapid commercialization of new patch‑based products.
Target Audience
The primary customers are pharmaceutical companies seeking to develop or extend chronic‑therapy portfolios with transdermal delivery, as well as healthcare providers and patients who require convenient, non‑invasive dosing options.
Features
- Polymer‑based drug reservoir with a rate‑controlling membrane that provides precise, zero‑order release kinetics over 24–72 hours
- Skin‑friendly, hypoallergenic adhesive layer engineered for consistent contact and minimal irritation across diverse patient populations
- Integrated safety lock that prevents accidental drug exposure during handling and ensures dose integrity until application
- Modular formulation platform supporting APIs ranging from 50 mg to 500 mg, including both small molecules and peptide therapeutics
- Scalable roll‑to‑roll manufacturing workflow compatible with existing GMP facilities, reducing time‑to‑market for new patches
- Tamper‑evident, child‑resistant packaging that meets FDA and EU regulatory standards for transdermal drug products
- Compatibility with digital health ecosystems via optional NFC tag for patch activation tracking and adherence monitoring